Terms: = Liver cancer AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Treatment
66 results:
1. CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma.
Abou-Alfa GK; Geyer SM; Nixon AB; Innocenti F; Shi Q; Kumthekar P; Jacobson S; El Dika I; Yaqubie A; Lopez J; Huang B; Tang YW; Wen Y; Schwartz LH; El-Khoueiry AB; Knox JJ; Rajdev L; Bertagnolli MM; Meyerhardt JA; O'Reilly EM; Venook AP
Cancer Res Commun; 2024 Mar; 4(3):682-690. PubMed ID: 38363156
[TBL] [Abstract] [Full Text] [Related]
2. Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma.
Pallerla SR; Hoan NX; Rachakonda S; Meyer CG; Van Tong H; Toan NL; Linh LTK; Giang DP; Kremsner PG; Bang MH; Song LH; Velavan TP
BMC Med Genomics; 2022 Nov; 15(1):235. PubMed ID: 36345011
[TBL] [Abstract] [Full Text] [Related]
3. Acteoside (Verbascoside): A Prospective Therapeutic Alternative against Hepatocellular Carcinoma by Inhibiting the Expression of AXL, FGFR, BRAF, TIE2 and raf1 Targets.
Kityania S; Nath R; Nath D; Patra JK; Talukdar AD
Comb Chem High Throughput Screen; 2023; 26(10):1907-1919. PubMed ID: 36321230
[TBL] [Abstract] [Full Text] [Related]
4. Arecoline promotes proliferation and migration of human HepG2 cells through activation of the PI3K/AKT/mTOR pathway.
Xie H; Jing R; Liao X; Chen H; Xie X; Dai H; Pan L
Hereditas; 2022 Jul; 159(1):29. PubMed ID: 35836300
[TBL] [Abstract] [Full Text] [Related]
5. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
Bray AW; Duan R; Malalur P; Drusbosky LM; Gourdin TS; Hill EG; Lilly MB
Prostate; 2022 Sep; 82(13):1264-1272. PubMed ID: 35766303
[TBL] [Abstract] [Full Text] [Related]
6. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer.
Rudalska R; Harbig J; Snaebjornsson MT; Klotz S; Zwirner S; Taranets L; Heinzmann F; Kronenberger T; Forster M; Cui W; D'Artista L; Einig E; Hinterleitner M; Schmitz W; Dylawerska A; Kang TW; Poso A; Rosenfeldt MT; Malek NP; Bitzer M; Laufer S; Pichler BJ; Popov N; Schulze A; Zender L; Dauch D
Nat Cancer; 2021 Feb; 2(2):201-217. PubMed ID: 35122079
[TBL] [Abstract] [Full Text] [Related]
7. Elevated expression of RIT1 hyperactivates RAS/MAPK signal and sensitizes hepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor.
Sun L; Xi S; Zhou Z; Zhang F; Hu P; Cui Y; Wu S; Wang Y; Wu S; Wang Y; Du Y; Zheng J; Yang H; Chen M; Yan Q; Yu D; Shi C; Zhang Y; Xie D; Guan XY; Li Y
Oncogene; 2022 Jan; 41(5):732-744. PubMed ID: 34845378
[TBL] [Abstract] [Full Text] [Related]
8. Gd-EOB-DTPA-enhanced magnetic resonance imaging may help identify patients with hepatocellular carcinoma eligible for treatment targeted at raf1.
Mo Z; Ding H; Zhou X; Zeng Z; Long L
Abdom Radiol (NY); 2022 Jan; 47(1):209-220. PubMed ID: 34738148
[TBL] [Abstract] [Full Text] [Related]
9. Predictive biomarkers for systemic therapy of hepatocellular carcinoma.
Moldogazieva NT; Zavadskiy SP; Sologova SS; Mokhosoev IM; Terentiev AA
Expert Rev Mol Diagn; 2021 Nov; 21(11):1147-1164. PubMed ID: 34582293
[No Abstract] [Full Text] [Related]
10. CXCR4 promotes gefitinib resistance of Huh7 cells by activating the c-Met signaling pathway.
Zhao D; Yang Z; Chen C; Zhang Z; Yu Y; Li Z
FEBS Open Bio; 2021 Nov; 11(11):3115-3125. PubMed ID: 34555268
[TBL] [Abstract] [Full Text] [Related]
11. Exploiting lipotoxicity for the treatment of liver cancer.
Rudalska R; Zender L; Dauch D
Br J Cancer; 2021 Nov; 125(11):1459-1461. PubMed ID: 34302061
[TBL] [Abstract] [Full Text] [Related]
12. C0818, a novel curcumin derivative, induces ROS-dependent cytotoxicity in human hepatocellular carcinoma cells in vitro via disruption of Hsp90 function.
Abdelmoaty AAA; Zhang P; Lin W; Fan YJ; Ye SN; Xu JH
Acta Pharmacol Sin; 2022 Feb; 43(2):446-456. PubMed ID: 33824458
[TBL] [Abstract] [Full Text] [Related]
13. LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.
Ma Y; Xu R; Liu X; Zhang Y; Song L; Cai S; Zhou S; Xie Y; Li A; Cao W; Tang X
Int J Med Sci; 2021; 18(6):1456-1464. PubMed ID: 33628103
[No Abstract] [Full Text] [Related]
14. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
El Dika I; Capanu M; Chou JF; Harding JJ; Ly M; Hrabovsky AD; Do RKG; Shia J; Millang B; Ma J; O'Reilly EM; Abou-Alfa GK
Cancer Med; 2020 Oct; 9(20):7453-7459. PubMed ID: 32841541
[TBL] [Abstract] [Full Text] [Related]
15. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
[TBL] [Abstract] [Full Text] [Related]
16. Litchi (Litchi chinensis Sonn.) flower proanthocyanidin fraction exhibited protective efficacy to suppress nickel-induced expression for vascular endothelial growth factor in HepG2 cells.
Lin JT; Chang YY; Chen YC; Liao PL; Yang DJ
J Food Biochem; 2019 Jul; 43(7):e12882. PubMed ID: 31353727
[TBL] [Abstract] [Full Text] [Related]
17. Prediction of sorafenib treatment-related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation.
Dong Z; Huang K; Liao B; Cai H; Dong Y; Huang M; Zhou X; Jia Y; Xu L; Luo Y; Li ZP; Feng ST
Eur Radiol; 2019 May; 29(5):2272-2282. PubMed ID: 30547202
[TBL] [Abstract] [Full Text] [Related]
18. Melatonin Inhibits the Progression of Hepatocellular Carcinoma through MicroRNA Let7i-3p Mediated raf1 Reduction.
Wang TH; Hsueh C; Chen CC; Li WS; Yeh CT; Lian JH; Chang JL; Chen CY
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30201903
[TBL] [Abstract] [Full Text] [Related]
19. Downregulation of raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
[TBL] [Abstract] [Full Text] [Related]
20. Significance of prohibitin domain family in tumorigenesis and its implication in cancer diagnosis and treatment.
Yang J; Li B; He QY
Cell Death Dis; 2018 May; 9(6):580. PubMed ID: 29784973
[TBL] [Abstract] [Full Text] [Related]
[Next]
